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Abstract
Neoplasms are highly dependent on glucose as their substrate for energy production
and are generally not able to catabolize other fuel sources such as ketones and fatty
acids. Thus, removing access to glucose has the potential to starve cancer cells and
induce apoptosis. Unfortunately, other body tissues are also dependent on glucose for
energy under normal conditions. However, in human starvation (or in the setting of
diet-induced ketogenesis), the body “keto-adapts” and glucose requirements of most
tissues drop to almost nil. Exceptions include the central nervous system (CNS) and
various other tissues which have a small but obligatory requirement of glucose. Our
hypothesized treatment takes keto-adaptation as a prerequisite. We then propose the
induction of severe hypoglycemia by depressing gluconeogenesis while administering
glucose to the brain. Although severe hypoglycemia normally produces adverse effects
such as seizure and coma, it is relatively safe following keto-adaptation. We hypothesize
that our therapeutic hypoglycemia treatment has potential to rapidly induce tumor cell
necrosis.
1 Introduction
In 1924, Otto Heinrich Warburg’s Nobel-prize winning research demonstrated that neoplastic
cells rely on anaerobic glycolysis for their metabolic needs. Almost a century later, the results
and implications of his findings are still hotly debated. It is now accepted that most tumors
derive the vast majority of their energy from glucose. This major weakness is an attractive
target for therapeutic intervention. However, basic physiology dictates that normal cells
would also be starved by severe hypoglycemia. As such, targeting cancer by exploiting this
metabolic weakness has not been proven fruitful to date.1 In fact, cancer treatment has
∗Electronic address: kapelner@qc.cuny.edu
†Electronic address: matthew.vorsanger@nyumc.org
1 There has been renewed interest with the success of positron emission tomography, a diagnostic tool
which detects glucose uptake by making use of 18-fluorine 2-deoxyglucose.
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moved away from broadly cytotoxic modalities towards highly targeted therapies (Aggarwal,
2010). Treatments of choice include monoclonal antibodies, tyrosine kinase inhibitors, and
induction of specific immune responses as well as others.
In this paper, we reexamine the possibility of therapeutic hypoglycemia as an antineo-
plastic treatment while simultaneously delivering glucose to the body tissues that require it.
Our main hypothesis is that the alterations in metabolism that occur in the starvation state,
namely neurologic adaptation to hypoglycemia, provide a means of safely inducing hypo-
glycemia. Of course, this proposal is not mutually exclusive with other standard treatments
such as radiation, chemotherapy and dietary supplementation.
The outline of the paper is as follows. Section 2 provides background on cancer cell
metabolism and reviews the known cytotoxic effects of hypoglycemia on cancerous cells.
Here, we justify the assumptions needed for our hypothesized treatment from the litera-
ture. The next two subsections are prerequisites for understanding the implementation of
our hypothesized treatment. Section 3.1 discusses the body’s theoretical minimum glucose
requirements during starvation as well as the concept of tissue keto-adaptation. Section 3.2
discusses ketogenic dieting as a viable alternative to starvation while retaining bodywide
minimal glucose needs. We outline our severe hypoglycemia therapy in detail in Section 3.3.
Section 4 concludes and discusses further extensions as well as potential concerns.
2 Background
Cancer is the result of multiple changes in the delicate balance of cell function. The root
cause of neoplastic transformation is still under serious debate. There are many theories:
cancer is primarily a genetic disease (Vogelstein et al., 2013), cancer is a disease of aberrant
metabolism due to dysfunctional respiration in malfunctioning mitochondria (Seyfried and
Shelton, 2010), cancer is due to overproduction of reactive oxygen species (Oleksyszyn et al.,
2014), as well as others.
Regardless of the cause, the majority of neoplastic cells feature an aberrant glucose meta-
bolism first discovered by Warburg et al. (1924) and now known as the “Warburg Effect.”
Normal cells metabolize glucose in two steps. First, glucose is broken down to create pyru-
vate and a small amount of adenosine triphosphate (ATP) in the cytosol (glycolysis). Second,
pyruvate is shuttled into mitochondria where it is fully oxidized to water and carbon dioxide
in the Krebs cycle. Even with enough oxygen, cancer cells do not seem to advance beyond
cytosolic glycolysis to employ the vastly more efficient (by a factor of 17 : 1) oxidative phos-
phorylation. Instead, they divert their pyruvate to produce lactic acid. This is oxymoroni-
cally known as “aerobic glycolysis;” cancer cells ferment even in conditions of normoxia. A
potential cause of this aberrant metabolism is that cancer cells only have a fraction of the
mitochondria available to normal cells and these mitochondria are structurally defective (see
a review by Pedersen, 1977 and see Elliott and Barnett, 2011 for an electron microscopy
study of mitochondria from breast carcinoma). Others say the cause is damaged glycolysis
regulation (Koppenol et al., 2011). Regardless, “all roads to the origin and progression of
cancer pass through the mitochondria” and the hallmark of cancer is malfunction in oxidative
phosphorylation to varying degrees (Seyfried et al., 2014).
This implies that cancer cells do not have access to non-glycolytic fuels that demand full
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oxidative combustion in the Krebs cycle, namely fatty acids and the ketone bodies beta-
hydroyxbutyrate (β-OHB) and acetoacetate (Holm et al., 1995; Sawai et al., 2004), two sub-
strates that are key players in our hypothesized treatment. Chang et al. (2013) demonstrated
that the glioma cells in their investigation lack enzymes that break down ketones. Such evi-
dence may explain why introduction of healthy mitochondria into cancer cell cytoplasm halts
carcinogenesis (see Seyfried, 2012, Chapter 11 for a review of these studies).
The relevant point to our hypothesis is that glucose is the predominant energy substrate
for most cancers (Gullino et al., 1967) with glycolytic rates 8-200 times higher than normal
tissues (Phelps, 2004, Chapter 5) while producing about 10% more ATP than normal cells
(Koppenol et al., 2011). Cancer has a large fuel requirement due to its high proliferation rate
and large need for antioxidants. In addition, high glucose consumption is necessary for inter-
mediaries required in biosynthetic pathways: ribose for nucleotides; glycerol, pyruvate and
citrate for lipids; amino acids; and nicotinamide adenine dinucleotide phosphate (NADPH)
via the pentose phosphate pathway (Deberardinis et al., 2008).
Glycolysis being the exclusive source of energy in cancer is hotly debated and may not be
true of all cancers throughout their lifespan; tumors may have varied bioenergetic profiles.
They may be glycolytic and/or oxidative (Jelluma et al., 2006; Moreno-Sa´nchez et al., 2007;
Martinez-Outschoorn et al., 2011; Jose et al., 2011; Carracedo et al., 2013). For the purposes
of this article, we address the majority of neoplasms which the consensus holds are exclusively
glycolytic. We await future research that will elucidate when and in which cancer lines our
hypothesized treatment is most applicable.
Thus, cancer should be particularly vulnerable to glucose / glycolytic substrate depriva-
tion. Starving cancer from glucose is not a novel idea; proposals to treat cancer via serum
hypoglycemia date back to an editorial in the New York Times (1887) and are abundant in
the recent literature (Woolf and Scheck, 2014; Simone et al., 2013; Fine et al., 2012, 2008;
Seyfried et al., 2008; Mavropoulos et al., 2006; Kim et al., 1978). Another idea would be to
inhibit glycolysis (e.g. Ganapathy-Kanniappan et al., 2010) but this is not the strategy we
propose due to its more universal cytotoxicity.
Even though the idea of cancer starvation is commonplace, there have been no well-
designed studies evaluating this premise. Why do they not exist? Simone et al. (2013) argues
that the absence of clinical trials is due to unclear diet implementation protocols. Financial
concerns are also a likely explanation. With the time and resources needed to produce a
high-quality clinical trial, it is unlikely that therapeutic hypoglycemia would produce an
adequate return-on-investment for a pharmaceutical company. At the time of this writing,
there are some trials proposed (e.g. Tan-Shalaby and Seyfried, 2013 and the list found in
Table 2 of Simone et al., 2013). There are many uncontrolled studies that are optimistic.
For example, Zuccoli et al. (2010) details the account of a woman who had spontaneous
remission (i.e. sudden disappearance of cancer) of glioblastoma multiforme after two months
on a diet formulated to lower serum glucose. Niakan (2010) concluded that over 1,000 similar
spontaneous remission are most likely due to hypoglycemia and hypoxia (arguably a direct
consequence of the hypoglycemia).
Pre-clinical animal studies demonstrate promising results by cutting cancer’s nutrient
supply (Mukherjee et al., 2002, 2004; Zhou et al., 2007; Otto et al., 2008; Mavropoulos et al.,
2009; Shelton et al., 2010; Stafford et al., 2010; De Lorenzo et al., 2011; Sivananthan, 2013;
Jiang and Wang, 2013). However, there are some studies that are inconclusive (e.g. Masko
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et al., 2010).
There are many creative in-vitro studies of glucose starvation. In Demetrakopoulos et al.
(1978), tumor cells were found to be highly sensitive to glucose deprivation. Spitz et al. (2000)
found that glucose withdrawal induces cytotoxicity in transformed fibroblasts and colorectal
cells which they argue is the result of oxidative stress. Buzzai et al. (2005) demonstrated that
activation of the commonly expressed oncogene Akt prevents cancer cells from metabolizing
non-glycolytic substrates. Jelluma et al. (2006) performed the first study of glucose with-
drawal on gliobastoma multiforme cells and found 90% cell death in 24 hours. The death
was not due to ATP depletion and could be rescued by a free radical scavenger, thereby
lending credence to the oxidative stress theory. Aykin-Burns et al. (2009) demonstrated that
glucose deprivation can induce cytotoxicity in human breast cancer cells and colon cancer
cells in-vivo. They argue these results are due to cancer being unable to synthesize reducing
agents such as NADPH and pyruvate which are needed en masse for detoxification of high
concentrations of free radicals due to mitochondrial abnormalities. Li et al. (2010) observed
growth inhibition and apoptosis in lung fibroblasts after glucose restriction and Priebe et al.
(2011) demonstrated cell death in ovarian cancer. Also, Graham et al. (2012) demonstrated
that glucose withdrawal slows the proliferation, induces hyperthermia, and possibly induces
cancer cell death in four gliobastoma cell lines.
Our proposal is a natural extension of previous cancer starvation proposals. We propose a
ketogenic diet which allows for the safe induction of severe hypoglycemia via gluconeogenesis
attenuation. The serum levels we propose are lower than have ever been proposed in the past
and we do so in order to starve cancer cells rapidly. We now turn to detailing this therapy.
3 Our Hypothesis
The next two sections provide background material about human starvation and ketogenic
dieting that is necessary for understanding our hypothesized treatment which we detail in
Section 3.3.
3.1 Starvation: Minimizing the Body’s Glucose Needs
The body’s glucose requirements are minimized during periods of starvation, which consti-
tutes a drastic transformation in the body’s energy metabolism. Broadly speaking, starvation
has five stages which are outlined in Table 1 below.
Normally by the end of the first day, hepatic glycogen stores are depleted and the liver
(and to a lesser extent, the kidneys) begin to produce glucose from pyruvate, glycerol and
amino acids. The vast majority of tissues in the body (such as skeletal muscle, the heart, and
most organs) are facultative in their choice of substrate for energy production. During this
period of glucose scarcity, they cut their glucose metabolism and increase their metabolism of
free fatty acids (FFAs). Starvation even at this early stage forces body tissues to switch from
glycolysis to lipid oxidation for their energy needs. The ketone bodies β-OHB, acetoacetate
and acetone are always present in the blood, but after a few days of starvation they begin to
be produced in large quantities in the liver. Most tissues of the body can metabolize ketones
(with the exception of acetone).
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Stage of Physiological Time
Starvation Description Period
1 Gastrointestinal absorption < 1 day
2 Glycogenolysis < 2 days
3 Gluconeogenesis ≥ 2 days
4 Ketosis ≥ 3 days
5 (prolonged) Decreased gluconeogenesis and increased ≥ 14 days
cerebral ketone consumption
Table 1: The five stages of starvation from the time of last ingestion (reprinted with slight
modifications from Cahill 1983, page 2).
Of special interest is stage 5 — prolonged starvation of two weeks and longer. Cells have
long since cut their uptake of glucose but now also cut their uptake of ketones. This change,
coupled with increased blood-brain-barrier permeability of ketones (Morris, 2005) we will
call “keto-adaptation.” During stage 5, most cells rely purely on FFAs for their metabolic
requirements (Robinson and Williamson, 1980). However, some tissues still retain a need
for glucose even after keto-adaptation. The largest consumer is the brain and CNS, whose
health is vital to the success of our hypothesis.2
How much glucose does the brain need? A typical brain glucose requirement is approx-
imately 144 g/day (Cahill, 1970, Figure 1). This is a preferential utilization but not an
obligatory utilization. This point is crucial to our hypothesis. During keto-adaptation, the
brain glucose requirement drops to approximately 44 g/day (Cahill, 1970, Figure 5).3
What supplies the energy that this difference of approximately 100 g/day of glucose
previously supplied? The ketone bodies β-OHB and acetoacetate in a 6:1 proportion (Owen
et al., 1967, Table 5). Note that the brain does not metabolize FFAs (Owen et al., 1967,
Table 4).4 In stage 5 starvation, ketone blood levels surge to 2.5-9.7 mmol/L which are in
contrast to a negligible level of 0.01 mmol/L in non-starving subjects. The brain will readily
use ketone bodies if they are available even in non-fasting periods, but under this condition
ketone usage is negligible (Sokoloff, 1973). Morris (2005) suspects that the brain’s ketone
metabolism was evolutionarily developed to ensure survival in times of glucose being scarce.
2 Note that erythrocytes, leukocytes and bone marrow also solely rely on glucose, but they only employ
glycolysis. Thus, the lactate and pyruvate waste products are reconstituted into glucose via the Cori cycle
in the liver using energy supplied by the breakdown of lipids. Therefore, these tissues have zero net glucose
consumption.
3 It is not known if the average brain can do with less than 44 g/day of glucose. We assume that if the
body can get away with providing less, it would do so. Why? Each gram of glucose conserved is one gram of
protein conserved. Protein sparing is essential during starvation since protein is man’s precious machinery
vital to cellular structure and function. Depletion of these reserves can limit long-term survival even with
massive lipid depots. This question can also be asked as follows: why are ketones unable to provide 100%
of the brain’s energy requirements? The answer is unknown and we posit two theories. First, there may be
incomplete β-OHB and acetoacetate transport to all cells of the CNS (Morris, 2005). Second, β-OHB and
acetoacetate can only be converted to energy via oxidative phosphorylation in mitochondria; these organelles
are scant in long and thin myelinated axons (Waxman et al., 1995, page 17). Here, we posit that some of the
brain’s energy production must default to glycolysis in the axoplasm.
4 This is a mystery as FFAs are able to cross the blood-brain-barrier and the brain is equipped with
beta-oxidation enzymes for their combustion (Morris, 2005).
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Cahill (1970) suspects that other body tissues slash their ketone consumption in favor of
FFA’s to ensure adequate substrate for the brain. Further, Cahill and Veech (2003) argue
that if metabolic adaptation to ketones did not exist, Homo sapiens could not have developed
such a large and advanced brain.
The fuel metabolism of stage 5 starvation is illustrated in Figure 1. Of special interest is
the inventory of the sources of gluconeogenesis that provide the 44 g/day CNS requirement:
stored triacylglycerols (15g), amino acids taken from muscle tissue and to a lesser extent other
tissues (20g), and pyruvate / lactate (14g), which is the end product of anaerobic glycolysis
(thus about a third of the glucose during starvation burned by the CNS is recycled back into
glucose via the Cori cycle).
Figure 1: Fuel sources and sinks in the daily metabolism of Stage 5 starvation assuming a
1500 calorie resting metabolism (inspired by Cahill, 1970, Figure 5).
Starvation can be a useful tool to minimize glucose needs in all but a few body tissues.
Fasting, while relatively safe (Stewart and Fleming, 1973), is not only unpleasant but leads
to muscle wasting and weight loss, both of which are serious concerns in cancer patients.
How do we minimize the body’s glucose needs while avoiding these undesired effects? We
turn to a solution in the next section.
3.2 Keto-adaptation via the 4:1 Ketogenic Diet
A means to emulate the metabolic conditions of starvation while still ingesting food is the
same engineering problem faced in the 1920’s by the expert childhood epileptologist Dr.
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Russel M. Wilder. He observed that short-term starvation was therapeutic for children with
intractable epilepsy, but obviously impractical as a long-term solution. He innovated the
“ketogenic diet” (KD) that mimics the characteristic starvation metabolism we outlined in
Section 3.1. It is still used today to reduce seizures (for an historical account and a recent
clinical trial, see Neal et al., 2008).
Wilder’s KD is a high fat, low protein and very low carbohydrate diet (McDonald, 1998).
To mimic starvation, strict macronutrient proportions are required. In what is called the
“4:1 KD,” carbohydrate must be limited to 20 g/day (the amount the muscle tissue provides
during prolonged starvation) and protein must be limited to an amount to offset normal
(non-starvation) protein turnover, estimated at about 25 g/day for a 70kg person (National
Research Council (US) Food & Nutrition Board, 1989). Any additional protein has the
potential to be gluconeogenic and thereby should be avoided. All other calories must be
supplied by fats.5 Commercial formulas for this diet are readily available.
Are the physiological markers in a prolonged 4:1 KD exactly the same as markers under
prolonged starvation? Depending on the macronutrient proportions, serum glucose can be
slightly higher and ketone levels slightly lower (Phinney et al., 1983). We assume that a 4:1
KD is equivalent to keto-adapted metabolism observed during prolonged starvation described
in Section 3.1: glucose uptake minimization, increased cerebral ketone uptake, and exclusive
use of FFAs for energy production in every other tissue in the body. Thus, a KD can achieve
starvation metabolism adaptation without the unpleasant side effects of hunger and muscle
loss.
Simone et al. (2013) also reviews other benefits of the KD such as muscle sparing and pos-
sibly even muscle synthesis which can be beneficial for cancer patients with risk of cachexia.
The KD is generally “well-tolerated with minimal side effects such as constipation, salt loss,
mild acidosis and increased incidence of kidney stones, when employed chronically” and has
been demonstrated to be safe even in patients with advanced cancer (Schmidt et al., 2011).
Kossoff et al. (2007) reports on the longest duration of a continuous KD: 21 years with vir-
tually no side effects. There is also some evidence that ketones in their own right are directly
toxic to cancer (Magee et al., 1979; Skinner et al., 2009; Fine et al., 2009) and can improve
the immune system’s ability to target cancer (Husain et al., 2013). This can be an added
benefit of the KD that can work in tandem with our hypoglycemia strategy.
Our hypothesized treatment begins with a cancer patient being administered a 4:1 KD
for more than 14 days to allow for keto-adaptation. Then our proposed acute treatment is
begun. We turn to implementation details now.
3.3 Our Proposed Treatment
Section 2 discussed previous literature that experimented with both starvation and the KD
for cancer therapy via glucose starvation. We believe these studies did not reduce serum
glucose to levels sufficient to starve the cancer. On a KD, “plasma glucose concentration falls
5 We detail the calculation here. 90% of the calories are supplied by triglycerides which are esters of three
fatty acid chains and one glycerol. 1/10th of fat calories are derived from the directly gluconeogenic glycerol.
Thus, 81% of dietary calories is supplied by fatty acids and 9% + 10% = 19% by other substrates yielding a
ratio of 81%/19% ≈ 4 : 1.
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only mildly, remaining in the normal range in normal-weight individuals ... [thus] ... simple
tumor glucose starvation is therefore unlikely in humans” (Fine et al., 2008).
Serum glucose in prolonged starvation drops to about 65mg/dL (Cahill, 1970, Table 2)
and the prolonged 4:1 KD can also result in a similar serum level, but it is unclear why
further reduction in the blood glucose level should not be similarly well-tolerated after keto-
adaptation.
In an adult, cerebral blood flow is approximately 750mL/min = 0.13 dL/s which implies
8.1mg/s of glucose can potentially be delivered to the brain. In Section 3.1, we noted that
the brain has an obligatory requirement of 44 g/day = 0.51 mg/s6 which is only 6% of the
glucose available at a serum concentration of 65 mg/dL. Although experiments evaluating
the glucose extraction ratio in human subjects are limited, animal studies suggest that the
brain is able to extract 40% of the serum glucose in the hypoglycemic state (McCall et al.,
1986). Thus, we theorize that the body is being conservative. Serum glucose concentrations
below the level where 0.51 mg/s can be actively transported into neurons for mere moments
can result in CNS damage; 65 mg/dL is comfortably above this threshold.
We have evidence for this conjecture that keto-adapted subjects can survive on serum
glucose much lower than 65mg/dL. Hypoglycemia has been reported in therapeutic fasting
or starvation for over 100 years. Chakrabarty (1948) investigated 407 starvation cases in
the Bengal famine to find that 20 or so of them had chronic blood sugar below 40 mg/dL
with no symptoms of hypoglycemia. Stewart and Fleming (1973) who supervised a world-
record-setting 382-day therapeutic fast found that blood glucose became stable at 30 mg/dL,
dropping intermittently to 20 mg/dL without symptoms. The most relevant evidence to
our hypothesis is the observation of intentional acute hypoglycemia induction by Drenick
et al. (1972) who keto-adapted obese patients via 45-60 days of starvation and then perfused
insulin. Within the hour, they observed serum glucose as low as 9 mg/dL without acute
hypoglycemic symptoms. Serum glucose this low would normally induce coma (which has
even been observed with blood sugar as high as 40-49 mg/dL according to Ben-Ami et al.,
1999, Figure 3).
Our plan is simple. After keto-adaptation with the 4:1 KD, we propose to acutely at-
tenuate the serum glucose concentration to severely hypoglycemic levels such as observed in
Drenick et al. (1972) on a patient-by-patient basis. Since insulin is required by cancer cells
and fuels their metabolism (Iqbal et al., 2013) and also can impede ketogenesis, we choose
not to induce hypoglycemia via insulin perfusion (as in Drenick et al., 1972), but instead
propose the use of a gluconeogenesis inhibitor.
One possible inhibitor is the diabetic drug metformin which inhibits gluconeogensis in-
directly. Metformin may have other anti-cancer effects (Jalving et al., 2010, Figure 3) and
there is certainly supporting epidemiological evidence for metformin’s therapeutic effect in
cancer (Ben Sahra et al., 2010). For these reasons, it has been proposed for use in a hy-
pothesized treatment similar to ours (see Oleksyszyn, 2011 and further in Oleksyszyn et al.,
2014). However, metformin has many drawbacks. First, it is not a potent inducer of hypo-
glycemia in the doses that are normally administered. Metformin is also slow acting and not
rapidly titratable. Additionally, the drug activates adenosine monophosphate activated pro-
6 This calculation is within 20% of the brain arteriovenous glucose difference observed in starving subjects
(Owen et al., 1967, Table 5).
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tein kinase which may have other effects on metabolism under keto-adaptation (see Jalving
et al., 2010, Figure 2). Lastly, supratherapeutic doses have been associated with fatal lactic
acidosis.
Due to these shortcomings, we propose using a drug which is a pure liver-kidney gluco-
neogenesis inhibitor. Luckily, these drugs have been investigated by the diabetes community
where high endogenous glucose production is considered one of the characteristics of the
disease and is therefore a therapeutic target.
There are many control points within gluconeogenesis. The unidirectional synthesis
of fructose-6-phosphate from fructose-1,6-bisphospate is a prudent point to interrupt be-
cause it is removed from glycogenolysis and mitochondrial function (thus, it would have the
fewest side effects). The synthesis is controlled via the rate-controlling enzyme fructose-1,6-
bisphosphatase. Two inhibitors that have been clinically evaluated are named CS-917 and
MB07803 (van Poelje et al., 2011). They have good safety profiles and can flexibly attenuate
gluconeogenesis to any desired level.
Returning to our discussion of the target level of hypoglycemia, we comment that we do
not know the effective dose (ED) curves for serum glucose levels for tumor necrosis or the or
lethal dose (LD) curves for human body death after keto-adaptation. It is possible that a 9
mg/dL glucose concentration may be too high to be toxic for the cancer. If this proves to be
the case, further hypoglycemia would need to be safely induced for treatment efficacy. We
turn to this now.
Since the brain is the only tissue with an obligatory glucose requirement, we opt for
direct perfusion of glucose into the brain intra-arterially via the carotid arteries at the rate
necessary to provide minimum brain glycolytic needs. Perfusion of glucose directly to the
brain has been performed successfully in rats (Borg et al., 1997) and baboons (Conway
et al., 1969). Once the brain receives its required glucose, we propose an increase in the
dose of gluconeogenic inhibitor drug to attenuate serum glucose to a negligible level which
is safe enough for erythocytes, blood marrow and leukocytes to survive. The brain would
perceive normoglycemia but everywhere outside of the brain the serum would be extremely
hypoglycemic. If necessary, we can also perfuse β-OHB in tandem if there is risk that the
level of ketosis is not sufficiently high for CNS metabolic needs. This protocol would require
extensive proof-of-concept work in animal models before any attempt to undertake study in
human subjects.
The reader may wonder if this strategy would be effective against brain cancer since the
brain is still receiving glucose. Seyfried et al. (2003) reports data supporting that such a
treatment may be effective since glucose uptake in brain cancers drops with lower serum
glucose and that the cancer cannot metabolize ketones, which may even be toxic to them.
How fast could this procedure induce tumor death? We echo Oleksyszyn et al. (2014),
“we do not have any idea as to how deep hypoglycemia needs to be to trigger spontaneous
remission.” All estimates are drawn from data from in-vitro studies and thus are not general-
izable to human prognoses. Spitz et al. (2000, Figure 2) reports between 55% and near 100%
necrosis rates in three cancer lines within 48hr after total glucose deprivation. Complete
withdrawal is not possible in the human body for reasons explained above and our treatment
could deliver minimum serum levels estimated at 5 mg/dL.
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4 Discussion
We propose a therapy for starving cancer by inducing keto-adaptation followed by the in-
duction of therapeutic hypoglycemia via gluconeogenesis inhibitor drugs. We then propose
rescue cerebral glucose infusion through direct catheterization of the brains’s blood supply.
This would be followed by an increase of the gluconeogenic inhibitor drug to lower serum
glucose even further in non-cerebral tissues.
A main concern is that each person is a “unique metabolic entity” (Seyfried et al., 2014).
The calculations presented throughout this manuscript are meant to be illustrative of an
average person. For each individual, personalized dosing and administration schedules will
require iterative fine-tuning.
Proper monitoring and its associated costs are a concern. Hypoglycemia is very risky but
might not necessarily require the monitoring setting of an intensive care unit (patients with
diabetic ketoacidosis are frequently treated with insulin infusion outside of the intensive care
unit). Although the costs of the diet and the medications needed to induce hypoglycemia in
our proposal might be far lower than the cost of novel chemotherapeutic agents, the cost of
close monitoring may substantially erode this benefit.
There are several other concerns with this speculative treatment. Cancer is heteroge-
neous and few predictors are currently available as to an individual tumor’s response to
hypoglycemia. There is research suggesting that some cancer cells can make use of ketones
and FFAs. Not all cancer lines proliferate rapidly and intense anabolism is not mandatory
(Jose et al., 2011). Our hypothesized treatment would not work in such cancer lines. It
is not known whether the proposed hypoglycemic levels can be sustained for long periods
of time without symptoms. Starvation research suggests that hypoglycemia is safe in the
long term, but these accounts documented serum levels many times above our proposed
serum level and they were predominantly documented in obese subjects without cancer. An
important consideration is whether keto-adaptation additionally protects against the neu-
rohormal cardiovascular and electrophysiologic consequences of hypoglycemia (Frier et al.,
2011). Additionally, glucose is not the sole nutritive substrate for cancer cells. For instance,
glutamine can also serve as a major metabolite (Yuneva, 2008), as well as fermentation from
other amino acids. We assume in our hypothesis that glucose is the necessary metabolite
where other metabolites have neither the availability nor the capability of being transported
in volumes necessary to serve as replacements. Lastly, there are times when the body is in
need of glucose such as during inflammation and infection which limits the setting of our
hypothesized treatment.
There is also a fair chance that our proposed treatment is more effective when provided
in tandem with other therapies. For instance, Abdelwahab et al. (2012) demonstrated that
brain cancer in mice was curtailed and did not recur with the simultaneous administration of
the 4:1 KD and radiation therapy. Allen et al. (2013) demonstrated that the 4:1 KD enhances
radio-chemo-therapy in mice models of lung cancer. See Klement and Champ (2014) for a
discussion of how the KD can act synergistically with radiation therapy. Also, Lee et al.
(2012) demonstrated that fasting enhances chemotherapy. Poff et al. (2013) demonstrated
that hyperbaric oxygen therapy is enhanced by the KD.
Alternative adjuvant therapies may also be fruitful. For example, Majumdar et al. (2009)
demonstrated that the combination of curcumin with resveratrol could be an effective therapy
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in colorectal cancer, Singh and Lai (2004) demonstrated cancer apoptosis from wormwood
extract and Tin et al. (2007) demonstrated that astralagus saponins can inhibit colorectal
cancer cell proliferation. There are many other such supplements that can be administered
simultaneously with our hypoglycemia treatment.
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